$Endocyte, Inc. (ECYT)$ 在asco上展示的前列腺癌数据惊人啊，In 50 treated patients, 62% (n=31) experienced greater than a 50% reduction in PSA (prostate-specific antigen) levels while 44% (n=22) experienced at least an 80% reduction in PSA. Median overall survival was 13.5 months for the first cohort of 30 patients.